Table 3 Potential prespecified sources of heterogeneity explored among the studies reporting an association between psoriasis and obesity
Prespecified source of heterogeneity | Number of estimates | Stratified fixed-effects meta-analysis OR (95% CI) | Meta-regression P-value for heterogeneity |
|---|---|---|---|
Study location | 0.78 | ||
USA | 1 | 2.39 (1.98–2.90) | |
Europe | 8 | 1.56 (1.31–1.86) | |
Other | 7 | 1.69 (1.39–2.06) | |
Source population | 0.09 | ||
Inpatient | 2 | 1.12 (0.89–1.41) | |
Outpatient | 14 | 1.75 (1.54–1.99) | |
Statistical adjustment | 0.004 | ||
Not adjusted | 6 | 2.32 (1.79–3.01) | |
Adjusted | 10 | 1.41 (1.26–1.58) | |
Study quality | 0.13 | ||
Lower (0–3) | 6 | 2.19 (1.70–2.81) | |
Higher (4–6) | 11 | 1.48 (1.30–1.68) | |
Outcome ascertainment | 0.86 | ||
Billing data | 1 | 1.72 (1.68–1.76) | |
Chart review | 11 | 1.66 (1.44–1.91) | |
Examination | 4 | 1.66 (0.97–2.83) | |
Analysis of outcome | 0.42 | ||
Primary | 11 | 1.75 (1.49–2.06) | |
Secondary | 5 | 1.48 (1.24–1.77) | |
Severity of psoriasis | 0.55 | ||
No distinction | 10 | 1.62 (1.32–1.97) | |
Mild vs severe | 6 | 1.74 (1.43–2.12) |
